

Xspray Pharma's Nomination Committee for the Annual General Meeting 2026

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee's composition for the Annual General Meeting, May 12, 2026.

The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 13 May 2025, consists of:

- Thomas Eldered, appointed by Flerie AB, Chairman of the Nomination Committee
- Johan Gyllenswärd, appointed by Ribbskottet AB
- Mattias Klintemar, appointed by The Foundation for Baltic and East European Studies
- Johan Wadell, appointed by AP2
- Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB

The Nomination Committee shall, before the Annual General Meeting on May 12, 2026, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual Meeting, election of auditors, the determination of fees and matters pertaining thereto.

Shareholders who wish to submit proposals to the Nomination Committee prior to the Annual General Meeting, can do so via e-mail to generalmeeting@xspray.com before March 24, 2026.

For further information about the Nomination Committee, please contact:
Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB
Email: anders.ekblom@xspray.com

For further information, please contact:

Jacob Nyberg, IR
Xspray Pharma AB (publ)
Tel: + 46 (0) 70 767 08 83
E-mail: ir@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development utilizing its innovative, patented HyNap™ technology platform to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology market segment, often with high drug prices. The company's goal is to become the market leader in improved PKI's for cancer treatment. Xspray Pharma's lead drug candidate, Dasynoc®, is currently undergoing FDA review. It is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose due to a better solubility profile. Its compatibility with proton pump inhibitors (PPIs), which are often co-prescribed to patients with CML and ALL, is a significant advantage. Xspray Pharma is building a robust product portfolio, including XS003-nilotinib (an optimized version of Tasigna®) and XS008-axitinib (an optimized version of Inlyta®) and XS025-cabozantinib (an optimized version of Cabometyx®).

The Xspray Pharma AB-share is trading at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com.

Attachments

[20251009_Xspray Pharma's Nomination Committee for the Annual General Meeting 2026](#)